NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00615-8441-39 | 00615-8441 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov 10, 2022 | In Use | |
00054-0017-20 | 00054-0017 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb 13, 2003 | In Use | |
00904-6552-61 | 00904-6552 | Ondansetron hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 26, 2006 | In Use | |
71335-1915-04 | 71335-1915 | Prednisone | PREDNISONE | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jul 20, 2021 | In Use | |
00093-9018-65 | 00093-9018 | Cyclosporine | Cyclosporine | 25.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Jun 8, 2021 | In Use | |
83047-0410-04 | 83047-0410 | Obecabtagene autoleucel | AUCATZYL | 10000000.0 /1, 100000000.0 /1, 300000000.0 /1 | Immunotherapy | CAR-T | CD19 | Intravenous | Nov 8, 2024 | In Use | |
83831-0134-01 | 83831-0134 | Leuprolide acetate | LUTRATE DEPOT | 22.5 mg/2ml | Hormonal Therapy | GnRH Agonist | Intramuscular | Mar 26, 2025 | In Use | ||
24979-0726-07 | 24979-0726 | Letrozole Tablets | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jan 10, 2025 | In Use | ||
64679-0636-02 | 64679-0636 | Octreotide Acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | May 11, 2011 | In Use | ||
00002-3977-60 | 00002-3977 | Selpercatinib | RETEVMO | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | May 8, 2020 | In Use | |
54868-6307-00 | 54868-6307 | Isotretinoin | Claravis | 20.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Sep 14, 2011 | In Use | |
71930-0078-50 | 71930-0078 | Hydrocortisone | Hydrocortisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct 7, 2022 | In Use | |
72603-0270-01 | 72603-0270 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | Nov 1, 2024 | In Use | |
67877-0171-30 | 67877-0171 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jun 28, 2010 | In Use | ||
65977-5025-04 | 65977-5025 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jun 7, 2010 | In Use | |
50242-0245-86 | 50242-0245 | Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf | Phesgo | 30000.0 U/15mL, 1200.0 mg/15mL, 600.0 mg/15mL | Immunotherapy | Monoclonal Antibody | HER2 | Subcutaneous | May 3, 2021 | In Use | |
68071-1904-06 | 68071-1904 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 22, 2017 | In Use | |
68071-3742-01 | 68071-3742 | PREDNISONE | PREDNISONE | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec 10, 2024 | In Use | |
00115-1408-03 | 00115-1408 | Methyltestosterone | Methyltestosterone | 10.0 mg/1 | Hormonal Therapy | Androgen | Oral | Sep 21, 2015 | In Use | ||
71205-0665-10 | 71205-0665 | Prednisone | Prednisone | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 26, 2022 | In Use | |
71205-0729-60 | 71205-0729 | PREDNISONE | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec 12, 2022 | In Use | |
71335-2389-08 | 71335-2389 | PREDNISONE | PREDNISONE | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 29, 2024 | In Use | |
00085-1381-01 | 00085-1381 | Temozolomide | Temodar | 2.5 mg/mL | Chemotherapy | Alkylating Agent | Tetrazine | Intravenous | Feb 27, 2009 | In Use | |
23155-0356-32 | 23155-0356 | Palonosetron Hydrochloride | Palonosetron Hydrochloride | 0.05 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Jun 29, 2021 | Jun 30, 2021 | In Use |
31722-0525-30 | 31722-0525 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Aug 1, 2010 | In Use |
Found 11564 results — Export these results